Peter Mohai, MD
Rheumatology · Seattle, WANPI 1831185966
Payments from drug & device makers
Across 659 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- AbbVie$2K
- Novartis$2K
- Pfizer$1K
- GSK$984
- Johnson & Johnson$676
- plus $3K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 128 | $2,652 |
| AbbVie | 137 | $2,371 |
| Novartis | 122 | $1,795 |
| Pfizer | 40 | $1,143 |
| GSK | 59 | $984 |
| Johnson & Johnson | 37 | $676 |
| E.r. Squibb & Sons, L.L.C. | 29 | $523 |
| UCB, Inc. | 23 | $410 |
| AstraZeneca(2 entities) | 13 | $298 |
| Aurinia Pharma U.S., Inc. | 14 | $277 |
| Sanofi | 8 | $185 |
| Lilly USA, LLC | 8 | $167 |
| Organon | 6 | $128 |
| Genentech USA, Inc. | 4 | $101 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $100 |
| Sobi, Inc | 3 | $81 |
| Regeneron Healthcare Solutions, Inc. | 2 | $78 |
| Tersera Therapeutics LLC | 3 | $77 |
| Octapharma USA, Inc. | 2 | $58 |
| ANI Pharmaceuticals, Inc. | 2 | $47 |
| Fresenius Kabi USA, LLC | 2 | $47 |
| Merck | 3 | $45 |
| Mallinckrodt Enterprises LLC | 2 | $38 |
| Pacira Therapeutics, Inc. | 2 | $36 |
| Vertex | 1 | $30 |
| Sandoz | 1 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| United Therapeutics Corporation | 1 | $16 |
| Si-bone, Inc. | 1 | $15 |
| Pharming Healthcare, Inc. | 1 | $15 |
How this compares
$12,467 in reported general payments places this provider in the 80th percentile of 157 rheumatology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Seattle
- Philip MeaseSeattle$5.1M
- Stanford PengSeattle$3.5M
- Jane BucknerSeattle$1.8M
- Kwang Hoon HanSeattle$1.5M
- Vivian StoneSeattle$232K
- Jeffrey CarlinSeattle$223K
- Anthony KrajcerSeattle$154K
- Florence HsuSeattle$31K
- Amish DaveSeattle$29K
- Namrata SinghSeattle$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.